Biolegend, 329903, FITC anti-human CD279 (PD-1) Antibody, 25tests

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.
25tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Fan XL, et al. 2018. Stem Cell Res Ther. 0.493055556. PubMed Li D, et al. 2023. Int J Oncol. 62:. PubMed Hu X, et al. 2023. Nat Biotechnol. . PubMed Sukegawa K, et al. 2020. Eur J Immunol. 50:1580. PubMed Zhang W, et al. 2022. Dev Cell. 57:329. PubMed Veatch JR, et al. 2022. Cancer Cell. 40:393. PubMed Pan R, et al. 2022. Cell. 185:1521. PubMed Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed Shitaoka K, et al. 2018. Cancer Immunol Res. 6:378. PubMed Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed Zhu W, et al. 2021. Onco Targets Ther. 14:2149. PubMed Ding L, et al. 2021. Cancers (Basel). 13:. PubMed Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed Hess NJ, et al. 2020. J Immunol. 205:272. PubMed Rueda C, et al. 2015. Hum Immunol. 76:65. PubMed Jiang N, et al. 2017. Lab Invest. 97:1364. PubMed Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed Yan Y, et al. 2018. JCI Insight. 3. PubMed Zhang J, et al. 2020. Nat Microbiol. . PubMed Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed Mudd PA, et al. 2022. Cell. 185:603. PubMed Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed Jones R, et al. 2009. J Virol. 83:8722. PubMed Jin C, et al. 2016. EMBO Mol Med. 8: 702 - 711. PubMed Ramaseri Sunder S, et al. 2020. J Interferon Cytokine Res. 40:310. PubMed Su Y, et al. 2020. Cell. 1479:183. PubMed Gao R, et al. 2018. Oncoimmunology. 7:e1438108. PubMed Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed Pierini S, et al. 2020. JCI Insight. 5:00. PubMed Nakamoto N, et al. 2009. PLoS One. 5:e1000313. PubMed Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
RRID: AB_940477 (BioLegend Cat. No. 329903) AB_940479 (BioLegend Cat. No. 329904)
Structure: Immunoglobulin superfamily
Distribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
Ligand/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Gene ID: 5133
UniProt: View information about CD279 on UniProt.org
Clone: EH12.2H7
Regulatory Status: RUO
Other Names: PD-1, PDCD1
Isotype: Mouse IgG1, κ